180 related articles for article (PubMed ID: 28882992)
1. Novel Pathways of Ponatinib Disposition Catalyzed By CYP1A1 Involving Generation of Potentially Toxic Metabolites.
Lin D; Kostov R; Huang JT; Henderson CJ; Wolf CR
J Pharmacol Exp Ther; 2017 Oct; 363(1):12-19. PubMed ID: 28882992
[TBL] [Abstract][Full Text] [Related]
2. In vitro metabolites characterization of ponatinib in human liver microsomes using ultra-high performance liquid chromatography combined with Q-Exactive-Orbitrap tandem mass spectrometry.
Gao L; Xu Q; Liu Q; Lang X
Biomed Chromatogr; 2020 Jun; 34(6):e4819. PubMed ID: 32112427
[TBL] [Abstract][Full Text] [Related]
3. Differential protection by human glutathione S-transferase P1 against cytotoxicity of benzo[a]pyrene, dibenzo[a,l]pyrene, or their dihydrodiol metabolites, in bi-transgenic cell lines that co-express rat versus human cytochrome P4501A1.
Kabler SL; Seidel A; Jacob J; Doehmer J; Morrow CS; Townsend AJ
Chem Biol Interact; 2009 May; 179(2-3):240-6. PubMed ID: 19330882
[TBL] [Abstract][Full Text] [Related]
4. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
5. BPDE-DNA adduct formation and alterations of mRNA, protein, and DNA methylation of CYP1A1, GSTP1, and GSTM1 induced by benzo[a]pyrene and the intervention of aspirin in mice.
Liu A; Li X; Zhou L; Yan X; Xia N; Song Z; Cao J; Hao Z; Zhang Z; Liang R; Zhang H
Environ Sci Pollut Res Int; 2023 Oct; 30(48):106549-106561. PubMed ID: 37730975
[TBL] [Abstract][Full Text] [Related]
6. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
7. Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450 1A1 and 1A2.
Stiborová M; Levová K; Bárta F; Shi Z; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Arlt VM
Toxicol Sci; 2012 Feb; 125(2):345-58. PubMed ID: 22086975
[TBL] [Abstract][Full Text] [Related]
8. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib.
Latifi Y; Moccetti F; Wu M; Xie A; Packwood W; Qi Y; Ozawa K; Shentu W; Brown E; Shirai T; McCarty OJ; Ruggeri Z; Moslehi J; Chen J; Druker BJ; López JA; Lindner JR
Blood; 2019 Apr; 133(14):1597-1606. PubMed ID: 30692122
[TBL] [Abstract][Full Text] [Related]
9. LC-ESI-MS/MS identification and characterization of ponatinib in vivo phase I and phase II metabolites.
Attwa MW; Kadi AA; Darwish HW; Amer SM; AlRabiah H
Clin Chim Acta; 2018 Oct; 485():144-151. PubMed ID: 29966620
[TBL] [Abstract][Full Text] [Related]
10. Cytochrome b5 and epoxide hydrolase contribute to benzo[a]pyrene-DNA adduct formation catalyzed by cytochrome P450 1A1 under low NADPH:P450 oxidoreductase conditions.
Stiborová M; Moserová M; Černá V; Indra R; Dračínský M; Šulc M; Henderson CJ; Wolf CR; Schmeiser HH; Phillips DH; Frei E; Arlt VM
Toxicology; 2014 Apr; 318():1-12. PubMed ID: 24530354
[TBL] [Abstract][Full Text] [Related]
11. Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition.
Mitchell R; Hopcroft LEM; Baquero P; Allan EK; Hewit K; James D; Hamilton G; Mukhopadhyay A; O'Prey J; Hair A; Melo JV; Chan E; Ryan KM; Maguer-Satta V; Druker BJ; Clark RE; Mitra S; Herzyk P; Nicolini FE; Salomoni P; Shanks E; Calabretta B; Holyoake TL; Helgason GV
J Natl Cancer Inst; 2018 May; 110(5):467-478. PubMed ID: 29165716
[TBL] [Abstract][Full Text] [Related]
12. Ponatinib Tyrosine Kinase Inhibitor Induces a Thromboinflammatory Response.
Hamadi A; Grigg AP; Dobie G; Burbury KL; Schwarer AP; Kwa FA; Jackson DE
Thromb Haemost; 2019 Jul; 119(7):1112-1123. PubMed ID: 31079415
[TBL] [Abstract][Full Text] [Related]
13. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein.
Buffa P; Romano C; Pandini A; Massimino M; Tirrò E; Di Raimondo F; Manzella L; Fraternali F; Vigneri PG
FASEB J; 2014 Mar; 28(3):1221-36. PubMed ID: 24297701
[TBL] [Abstract][Full Text] [Related]
15. Mass spectrometric characterization of protein adducts of multiple P450-dependent reactive intermediates of diclofenac to human glutathione-S-transferase P1-1.
Boerma JS; Dragovic S; Vermeulen NP; Commandeur JN
Chem Res Toxicol; 2012 Nov; 25(11):2532-41. PubMed ID: 22998212
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of aryl hydrocarbon receptor transactivation and DNA adduct formation by CYP1 isoform-selective metabolic deactivation of benzo[a]pyrene.
Endo K; Uno S; Seki T; Ariga T; Kusumi Y; Mitsumata M; Yamada S; Makishima M
Toxicol Appl Pharmacol; 2008 Jul; 230(2):135-43. PubMed ID: 18372000
[TBL] [Abstract][Full Text] [Related]
17. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen aristolochic acid I: studies in Cyp1a1-/-, Cyp1a2-/-, and Cyp1a1/1a2-/- mice.
Arlt VM; Levová K; Bárta F; Shi Z; Evans JD; Frei E; Schmeiser HH; Nebert DW; Phillips DH; Stiborová M
Chem Res Toxicol; 2011 Oct; 24(10):1710-9. PubMed ID: 21932800
[TBL] [Abstract][Full Text] [Related]
18. Apiaceous vegetable consumption decreases PhIP-induced DNA adducts and increases methylated PhIP metabolites in the urine metabolome in rats.
Kim JK; Gallaher DD; Chen C; Yao D; Trudo SP
J Nutr; 2015 Mar; 145(3):442-51. PubMed ID: 25733458
[TBL] [Abstract][Full Text] [Related]
19. Bioactivation of fluorinated 2-aryl-benzothiazole antitumor molecules by human cytochrome P450s 1A1 and 2W1 and deactivation by cytochrome P450 2S1.
Wang K; Guengerich FP
Chem Res Toxicol; 2012 Aug; 25(8):1740-51. PubMed ID: 22734839
[TBL] [Abstract][Full Text] [Related]
20. Bioactivation of isothiazoles: minimizing the risk of potential toxicity in drug discovery.
Teffera Y; Choquette D; Liu J; Colletti AE; Hollis LS; Lin MH; Zhao Z
Chem Res Toxicol; 2010 Nov; 23(11):1743-52. PubMed ID: 20825217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
